Board of Directors
Pr. Dr. Christof Hettich,
Chairman of the Board (representing Hopp Family)
Director: John Tchelingerian, PhD
(CEO and Series A Director)
Director: Alain Parthoens
(representing Vesalius BioCapital)
Director: Dr Ilka Wicke
(representing Boehringer Ingelheim Venture Fund)
Director: Kinji Fuchikami
(representing Mitsui & Co Global Investments)
Director: Philippe Degive
Director: Pr Etienne Sokal
(Founder and Series A Director)
Director: Dr Jean-Paul Prieels
Observer: Ingo Koesfeld
Observer: Charlie Alexander
Dr John Tchelingerian is a serial entrepreneur and a private investor. His background includes strong scientific, business, managerial and deal making experience. He has co-founded and managed several biotech companies including Neurotech, Key-Obs and Diatos. In the past ten years he has raised over $100 million (€ 81 million) for his entrepreneurial ventures from VCs and private equity sources in Europe, the US and Japan. He has also closed several biotech and pharma partnering deals. Under his leadership four drugs were developed from the research stage up to clinical phase IIb/III and a marketed drug, DaunoXome, was re-launched in a cancer orphan indication both in the USA and the EU, based on phase III clinical trials.
John co-founded a strategic advisory and corporate finance firm Silver Ocean Ventures in 2009; based in Paris. It primarily services the global life sciences industry regarding corporate finance, strategic business transactions and active board and leadership roles. Under his leadership Silver Ocean Ventures has closed several international capital raising and M&A transactions. As a scientist, John has invented several patents in the field of cell therapy and drug delivery.
He is a PhD graduate in Neurosciences from Pierre et Marie Curie University in Paris, France. He is fluent in five languages.
Pr Etienne Sokal is a medical entrepreneur and innovation driven; he founded Promethera on February 12th 2009, with the UCL Technology Transfer Office (Sopartec-LTTO).
He is CSO & CIO of Promethera Biosciences and member of the board.
He is a paediatric hepatologist with 30 years experience in the fields of liver diseases and liver transplantation. He is head of the Paediatric gastroenterology and hepatology service at Cliniques Universitaires St Luc (Brussels, Belgium) and full professor at Université Catholique de Louvain (UCL) (Belgium). More than 1000 children from many different countries have received liver transplantation at St Luc, and many others have been treated for various acquired or congenital liver diseases, including liver based metabolic disorders.
Prof E Sokal is heading the UCL lab of pediatric hepatology and cell therapy laboratory (Institute of Experimental and Clinical Research); he discovered Hepastem in 2005 and obtained several additional patents in the filed of stem cells.
More than 300 peer-reviewed publications (Scopus h index 55) demonstrate the level of excellence of the team, which is internationally recognized. The recent breakthrough in liver stem cell technology has also positioned the team within the leaders.
Frank Hazevoets is a highly experienced senior financial executive with over twenty-five years international business experience. He trained at the Catholic University of Leuven (KUL) in Belgium as a commercial engineer and also obtained a master degree in Artificial Intelligence and Cognitive Science. He has worked in leading positions in corporate finance and investment banking (Puilaetco, BACOB/Smeets Securities, BBL/ING), strategy and business development (InBev). During his six years as CFO at Tigenix, he supported the company in its funding and growth strategy and helped them to obtain the first European marketing authorization for cell-based medicinal products in Europe.
MBA and PhD in Finance from the European Business School, Germany<br\> Executive in the life science industry with over 15 years of U.S. and European experience in public and private biopharmaceutical companies.<br\> Former Co-CEO and CBO of Cytonet, Co-CEO and CFO of Agennix, CFO of GPC Biotech
Patrick Stragier is the Vice Persident of Operations, in charge of Manufacturing and Quality Control at Promethera Biosciences.
Biochemist with more than 25 years of international operational and managerial experience, he has worked for biopharmaceutical companies such as Solvay, DSM-Biologics, Genzyme and Lonza.
Since 2009, he has been working as a consultant specialized in cell therapy. He is the co-founder of MaSTherCell. Patrick Stragier joined Promethera Biosciences in September 2015.
Mustapha Najimi is a senior researcher at at the Experimental and Clinical Research Institute of the Université catholique de Louvain (UCL) (Belgium). He was a member of the founding team of Promethera Biosciences and is co-owner of 2 patents on HHALPC.
He earned his doctoral degree (Cell & Molecular Biology) in 1999 at the Université Pierre & Marie Curie in Paris. Dr Najimi is currently leading the Stem cells’ group and Cell culture platform at the Pediatric Hepatology & Cell Therapy laboratory (UCL, Belgium). Dr Najimi is the scientific supervisor of the hepatocytes and hepatic stem cells banks at Saint-Luc Hospital (Brussels, Belgium).
His main research interest is focused on hepatic stem cells biology and liver regeneration. He is invited reviewer for several journals of Hepatology and Cell Therapy fields.
PROMETHERA Biosciences S.A./N.V.
Watson & Crick Hill
Rue Granbonpré, 11
Tél.: +32 (0)10 39 43 00
Fax: +32 (0)10 39 43 01